News
03-12-2026, 05:40 AM
VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, today announced it has secured ?3 million to advance its lead antibody-drug conjugate (ADC) program.
More... (https://www.news-medical.net/news/20260312/VALANX-Biotech-secures-e282ac3-million-to-advance-LIV-1-ADC-for-metastatic-triple-negative-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20260312/VALANX-Biotech-secures-e282ac3-million-to-advance-LIV-1-ADC-for-metastatic-triple-negative-breast-cancer.aspx)